

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



12th August 2025

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code – 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.
Scrip Code–
APOLLOHOSP
ISIN INE437A01024

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

This has reference to our letters dated 23rd June and 16th July 2025, regarding the captioned subject. The Board at its meeting held today transacted the following items of business.

1. Financial Results

- Unaudited financial results (both standalone and consolidated) of the Company for the three months ended 30th June 2025, which have been subjected to Limited Review by the Statutory Auditors of the Company – as Annexure I.
- Copy of the Limited Review Report of the Statutory Auditors for the corresponding period.
- The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.
- The said documents are being posted on the website of the Company i.e., www.apollohospitals.com.

2. Acquisition of 50% stake held by Parkway Healthcare (Mauritius) PTE Limited in Gleneagles PET-CT Private Limited ("AGPCL")

The Board of Directors of the Company has approved an investment of an amount not exceeding a sum of ₹85 million for acquiring 85,00,000 equity shares of ₹10/- each of Apollo Gleneagles PET-CT Private Limited ("AGPCL") from its existing shareholder, Parkway Healthcare (Mauritius) PTE Limited, representing 50% of the total paid-up equity share capital of AGPCL.

IS/ISO 9001 : 2000

Regd. Office :

19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :

"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.



Tel : 044 - 2829 0956 / 3896 / 6681

Telefax : 044 - 2829 0956

Email : investor.relations@apollohospitals.com

Website : www.apollohospitals.com

Upon completion of the proposed transaction, AGPCL will become a wholly owned subsidiary of the Company.

The detailed disclosure as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/ 0155 dated November 11, 2024 is enclosed herewith as Annexure I.

3. Grant of Stock Options under Apollo ESOP Plan 2024

In pursuance to the approval obtained from the Members at the Annual General Meeting held on 30th August 2024 and based on the recommendations of NRC, the Board has considered and approved the grant of 327,494 stock options representing 327,494 equity shares of INR 5/- each to the eligible employees of the Company under the Apollo Hospitals Enterprise Limited Employee Stock Option Plan 2024 (Apollo ESOP 2024).

The detailed disclosure as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/ 0155 dated November 11, 2024 is enclosed herewith as Annexure II.

You are requested to kindly take note of the same.

The meeting of the Board of Directors commenced at 2.50 p.m and concluded at 6.35 p.m.

Please take note of the same in your records.

Thanking You

Yours faithfully
For APOLLO HOSPITALS ENTERPRISE LIMITED



S.M. KRISHNAN
Sr. VICE PRESIDENT – FINANCE
AND COMPANY SECRETARY



APOLLO HOSPITALS ENTERPRISE LIMITED



CIN : L85110TN1979PLC008035

Annexure - I

Sr. No	Particulars	Target Company								
		Apollo Gleneagles PET-CT Private Limited (AGPCL)								
1	Name of the Target Company, details in brief such as size, turnover, etc	AGPCL is engaged in the business of providing high-end medical diagnostic services through its state-of-the art PET-CT Radio Imaging Centre in Hyderabad. The turnover of AGPCL for the financial year ended March 31, 2025 was Rs. 202.00 million.								
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	No. The transaction does not fall within the ambit of a related party transaction and no promoter group companies have any interest in AGPCL								
3	Industry to which the entity being acquired belongs	Healthcare Services								
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The object is to consolidate ownership and have full control over AGPCL's operations, enabling better integration with the Company's diagnostic services and improving operational efficiencies								
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable								
6	Indicative time period for completion of the acquisition	The acquisition of the shares are expected to be completed by end August 2025, subject to completion of customary closing formalities.								
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration								
8	Cost of acquisition or the price at which the shares are acquired	Acquisition of 85,00,000 equity shares of AGPCL aggregating to Rs. 85 million.								
9	Percentage of shareholding/ control acquired and/or number of shares acquired	Upon completion of the Proposed acquisition of shares, AGPCL will become a wholly owned Subsidiary of the Company.								
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	AGPCL was incorporated under the Companies Act, 1956 on 24 th March 2004. AGPCL is currently engaged in providing healthcare services. The turnover of AGPCL for last 3 years is given below: <table border="1"> <thead> <tr> <th>Year</th> <th>Turnover (Rs. in Million)</th> </tr> </thead> <tbody> <tr> <td>2023-2024</td> <td>182.38</td> </tr> <tr> <td>2022-2023</td> <td>165.60</td> </tr> <tr> <td>2021-2022</td> <td>144.80</td> </tr> </tbody> </table> Country of presence of AGPCL : India	Year	Turnover (Rs. in Million)	2023-2024	182.38	2022-2023	165.60	2021-2022	144.80
Year	Turnover (Rs. in Million)									
2023-2024	182.38									
2022-2023	165.60									
2021-2022	144.80									

IS/ISO 9001 : 2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com



APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



Annexure - II

Sr. No	Particulars	Details										
1.	Brief details of options granted	327,494 options granted to eligible employees of the Company under Apollo ESOP 2024 Each Option upon exercise would be entitled for allotment of one equity share of INR 5/- each of the Company.										
2.	Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021	Yes										
3.	Total number of shares covered by these options	327,494 Equity shares of face value INR 5/- each of the Company.										
4.	Pricing formula / Exercise Price	Rs. 5,258/- per share which is at a 20% discount to the weighted average market price calculated for the period April 2024 to March 2025										
5.	Vesting Schedule	In terms of Apollo ESOP Plan 2024 and subject to the achievement of performance conditions as specified in grant letter, Options will vest as under: <table border="1" style="margin-left: 20px;"> <thead> <tr> <th>Time period</th> <th>Options vested</th> </tr> </thead> <tbody> <tr> <td>After 1 year from the date of the grant</td> <td>Nil</td> </tr> <tr> <td>After 2 years from the date of the grant</td> <td>40% of the options granted</td> </tr> <tr> <td>After 3 years from the date of the grant</td> <td>30% of the options granted</td> </tr> <tr> <td>After 4 years from the date of the grant</td> <td>30% of the options granted</td> </tr> </tbody> </table>	Time period	Options vested	After 1 year from the date of the grant	Nil	After 2 years from the date of the grant	40% of the options granted	After 3 years from the date of the grant	30% of the options granted	After 4 years from the date of the grant	30% of the options granted
Time period	Options vested											
After 1 year from the date of the grant	Nil											
After 2 years from the date of the grant	40% of the options granted											
After 3 years from the date of the grant	30% of the options granted											
After 4 years from the date of the grant	30% of the options granted											
6.	Time within which Options may be exercised	The vested Options shall be exercisable within a period of 3 years from the respective dates of vesting.										
7.	Options exercised	Not Applicable										
8.	Money realized by exercise of Options											
9.	The total number of shares arising as a result of exercise of Option											
10.	Options lapsed											
11.	Variation of terms of Options											



IS/ISO 9001 : 2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



12.	Brief details of significant terms	Apollo ESOP Plan 2024 was introduced to attract, reward and retain talented and eligible employees of the Company and encourage them to align individual performance with the Company's objectives. Options granted under the Scheme shall vest on satisfaction of vesting conditions which can thereafter be exercised resulting in allotment of equity shares of the Company.
13.	Subsequent changes or cancellation or exercise of such Options	Not Applicable
14	Diluted earnings per share pursuant to issue of equity shares on exercise of Options	



IS/ISO 9001 : 2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Standalone Financial Results for the three months ended June 30, 2025

(Rs. in Million)

Particulars	Three months ended 30/06/2025	Preceding three months ended 31/03/2025	Corresponding three months ended 30/06/2024	Previous year ended 31/03/2025
	Unaudited	Refer Note 2	Unaudited	Audited
1 Income				
(a) Revenue from operations	21,679	20,753	19,366	82,021
(b) Other income	325	916	273	3,477
Total Income (a + b)	22,004	21,669	19,639	85,498
2 Expenses				
(a) Cost of materials consumed	5,897	5,620	5,362	22,484
(b) Employee benefits expense	4,037	4,102	3,807	15,968
(c) Finance costs	588	631	635	2,540
(d) Depreciation and amortisation expenses	1,232	1,298	1,029	4,494
(e) Other expenses	6,284	5,818	5,489	23,127
Total Expenses	18,038	17,469	16,322	68,613
3 Profit before tax (1) - (2)	3,966	4,200	3,317	16,885
4 Tax expense				
Current tax	893	992	811	4,055
Deferred tax	4	(126)	(11)	(133)
5 Profit after tax for the period / year (3) - (4)	3,069	3,334	2,517	12,963
6 Other comprehensive income/(loss)				
Items that will not be reclassified to profit or loss				
(a) Remeasurement gains/(losses) on defined benefit plans	76	2	67	3
Income tax relating to items that will not be reclassified to profit or loss	(19)	(0)	(17)	(1)
Total other comprehensive income/ (loss)	57	1	50	2
7 Total comprehensive income for the period/year (5) + (6)	3,126	3,335	2,567	12,965
8 Paid-up equity share capital (Face value Rs.5/- per share)				719
9 Reserves (excluding Revaluation reserves)				86,623
10 Earnings per equity share of Rs.5/- each				
Basic and diluted earnings per share for the period/year (Rs.)	*21.35	*23.18	*17.51	90.15
11 Additional Information :-				
Earnings before finance costs, tax, depreciation and amortization, other income, exceptional items (EBITDA) (refer foot note)	5,461	5,213	4,708	20,442

*Not annualised

Foot note:

1 The Company has presented EBITDA additionally as part of standalone financial results.

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
 Managing Director

7. The Board approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.
8. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai
Date: August 12, 2025

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

NOTES TO STANDALONE FINANCIAL RESULTS:

1. The standalone financial results of Apollo Hospitals Enterprise Limited ("the Company") for the three months ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 11, 2025 and August 12, 2025 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three months ended June 30, 2025.
2. The standalone financial results for the three months ended March 31, 2025 are the balancing figures between the audited standalone figures of the full financial year ended March 31, 2025 and the unaudited year to date standalone figures for the nine months ended December 31, 2024, which was subject to limited review.
3. The standalone financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.
4. The Company's business activity primarily falls within a single reportable business segment namely "Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".
5. On 10th June 2025, the Company acquired 450,000 equity shares of Rs.2/- each of Apollo HealthTech Limited from the existing shareholders at par value, for a total consideration of Rs.9,00,000/- and consequent to the said acquisition, Apollo HealthTech Limited became a wholly owned subsidiary of the Company
6. The Board at its meeting held on 30th June 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230-232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited (collectively, "**Stock Exchanges**") and admission to trading.

The scheme has since been filed with stock exchanges for approval.

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Apollo Hospitals Enterprise Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Company"), for the three months ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Chennai
Date: August 12, 2025

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Nachiappan Subramanian
Partner
Membership No. 218727
UDIN: 25218727BMOEJB4950

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of consolidated financial results for the three months ended June 30, 2025

(Rs. in Million)

Particulars	Three months ended 30/06/2025	Preceding three months ended 31/03/2025	Corresponding three months ended 30/06/2024	Previous year ended 31/03/2025
	Unaudited	Refer Note 2	Unaudited	Audited
1 Income				
(a) Revenue from operations	58,421	55,922	50,856	217,940
(b) Other income	402	611	372	2,003
Total Income (a + b)	58,823	56,533	51,228	219,943
2 Expenses				
(a) Cost of materials consumed	7,401	6,944	6,901	27,544
(b) Purchases of stock-in-trade	23,155	22,436	19,107	85,567
(c) Changes in inventories of stock-in-trade	(80)	(94)	222	(11)
(d) Employee benefits expense	7,126	7,246	6,581	27,692
(e) Finance costs	1,083	1,148	1,164	4,585
(f) Depreciation and amortisation expense	2,147	2,110	1,774	7,575
(g) Other expenses	12,300	11,693	11,294	46,930
Total expenses	53,132	51,483	47,043	199,882
3 Profit/(loss) before share of profit/(loss) in associates / joint ventures and exceptional items (1) - (2)	5,691	5,050	4,185	20,061
4 Share of profit/(loss) of associates /joint ventures	136	105	115	330
5 Profit before tax (3) + (4)	5,827	5,155	4,300	20,391
6 Tax expenses				
Current tax	1,248	1,190	1,130	5,263
Deferred tax	169	(180)	15	77
7 Profit/(Loss) for the period/year (5) - (6)	4,410	4,145	3,155	15,051
8 Other Comprehensive Income				
Items that will not be reclassified to Profit or Loss				
Remeasurement gains / (losses) on defined benefit plan	61	(36)	52	(84)
Equity instruments through other comprehensive income	-	(2)	-	(2)
Income tax relating to items that will not be reclassified to profit or loss	(2)	9	-	17
Items that will be reclassified to Profit or Loss				
Exchange differences in translating the financial statements of foreign operations	(0)	(1)	(0)	6
Total other comprehensive income/ (expense)	59	(30)	52	(63)
9 Total comprehensive income / (expense) for the period/year (after tax) (7) + (8)	4,469	4,115	3,207	14,988
Profit / (Loss) for the period attributable to:				
Owners of the parent	4,328	3,896	3,052	14,459
Non-controlling interest	82	249	103	592
Other comprehensive income/ (expense) for the period attributable to:				
Owners of the parent	60	(25)	52	(50)
Non-controlling interest	(1)	(5)	-	(13)
Total comprehensive income / (expense) for the period attributable to:				
Owners of the parent	4,388	3,871	3,104	14,409
Non-controlling interest	81	244	103	579
10 Paid-up equity share capital (Face value Rs.5/- per share)				719
Reserves (excluding revaluation reserves)				81,326
11 Earnings per equity share of Rs.5/- each				
Basic and Diluted EPS for the period/year (Rs.)	*30.10	*27.10	*21.23	100.56

*Not annualised

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities

(Rs. in Million)

Particulars	Three months ended 30/06/2025	Preceeding three months ended 31/03/2025	Corresponding three months ended 30/06/2024	Previous year ended 31/03/2025
	Unaudited	Refer Note 2	Unaudited	Audited
1. Segment Revenue				
a) Healthcare services	29,738	28,431	26,536	112,201
b) Retail health & diagnostics	4,351	3,940	3,661	15,535
c) Digital health & pharmacy distribution	24,719	23,763	20,821	90,930
d) Others	13	12	12	48
SUB - TOTAL	58,821	56,146	51,030	218,714
Less : Intersegmental revenue	400	224	174	774
Income from operations	58,421	55,922	50,856	217,940
2. Segment Results				
a) Healthcare services	5,619	5,264	4,902	21,295
b) Retail health & diagnostics	71	118	27	300
c) Digital health & pharmacy distribution	692	230	73	1,127
d) Others	(10)	(25)	(25)	(79)
SUB - TOTAL	6,372	5,587	4,977	22,643
Less: (i) Finance cost	1,083	1,148	1,164	4,585
Add: (ii) Other un-allocable income, (net of expenditure)	402	611	372	2,003
Add: (iii) Share of profit/(loss) of associates / joint ventures	136	105	115	330
Profit Before Tax	5,827	5,155	4,300	20,391
3. Capital employed				
a) Healthcare services *				
Segment assets	129,519	127,403	117,049	127,403
Segment liabilities	(42,263)	(41,107)	(36,097)	(41,107)
b) Retail health & diagnostics				
Segment assets	14,094	13,277	13,218	13,277
Segment liabilities	(11,572)	(11,005)	(9,620)	(11,005)
c) Digital health & pharmacy distribution				
Segment assets	30,614	29,629	24,099	29,629
Segment liabilities	(10,041)	(10,206)	(11,383)	(10,206)
d) Others				
Segment assets	273	280	294	280
Segment liabilities	(178)	(179)	(175)	(179)
e) Unallocated				
Segment assets	38,814	35,984	15,907	35,984
Segment liabilities	(57,994)	(57,547)	(36,209)	(57,547)
Total	91,266	86,529	77,083	86,529
* Includes Capital employed in various hospital projects under construction	8,423	9,210	8,998	9,210

For APOLLO HOSPITALS ENTERPRISE LTD


 SUNEETA REDDY
 Managing Director

NOTES TO CONSOLIDATED FINANCIAL RESULTS:

1. The consolidated financial results of Apollo Hospitals Enterprise Limited ("the Company") for the three months ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 11, 2025 and August 12, 2025 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three months ended June 30, 2025.
2. The consolidated financial results for the three months ended March 31, 2025 are the balancing figures between the audited consolidated figures of the full financial year ended March 31, 2025 and the unaudited year to date consolidated figures for the nine months ended December 31, 2024, which was subject to limited review.
3. On 10th June 2025, the Company acquired 450,000 equity shares of Rs.2/- each of Apollo HealthTech Limited from the existing shareholders at par value, for a total consideration of Rs.9,00,000/- and consequent to the said acquisition, Apollo HealthTech Limited became a wholly owned subsidiary of the Company.
4. The Board at its meeting held on 30th June 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") – Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230-232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited (collectively, "**Stock Exchanges**") and admission to trading.

The scheme has since been filed with stock exchanges for approval.

5. The Board approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

6. The Honourable High Court of Karnataka on October 8, 2021 set aside the order of the Revenue Department, State of Karnataka ("Revenue Department") initiated earlier against a subsidiary alleging non-compliance of certain conditions associated with the allotment of land to the subsidiary and had directed the Revenue Department to reconsider and dispose the matter. The Revenue Department had issued a show cause notice dated February 9, 2022 seeking explanations as to why the original order needs to be withdrawn, for which the subsidiary had filed a detailed response explaining how there are no violations of the conditions relating to the allotment of the land. Based on an external legal opinion received, the subsidiary has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in its favour.

7. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai
Date: August 12, 2025

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associates and joint ventures for the three months ended 30th June 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited (AHEL)	Parent
Apollo Home Healthcare Limited (AHHL)	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary



**Deloitte
Haskins & Sells LLP**

Name of the Company	Relationship
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Apollo Nellore Hospital Limited	Subsidiary
Sapien Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital Private Limited (ARHPL)	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited (Assam)	Subsidiary
Apollomedics International Lifesciences Limited	Subsidiary
Apollo Multi Specialty Hospitals Limited (AMSHL)	Subsidiary
Apollo HealthCo Limited (AHL)	Subsidiary
Apollo Hospitals North Limited	Subsidiary
Kerala First Health Services Private Limited (KFHS)	Subsidiary
Health Axis Private Limited (HAPL)	Subsidiary
Apollo Hospitals Jammu and Kashmir Limited	Subsidiary
Apollo Hospitals Worli LLP (w.e.f. 12 July 2024)	Subsidiary
Apollo Healthtech Limited (w.e.f. 10 June 2025)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Care Diagnostics Private Limited (w.e.f. 1 February 2025)	Subsidiary of AHLL
Sobhagya Hospital and Research Centre Private Limited	Subsidiary of ARHPL
Apollo Fertility Centre Private Limited (Formerly known as Surya Fertility Centre Private Limited)	Stepdown Subsidiary of AHLL
Apollo Spectra Centres Private Limited (Formerly known as Kshema Healthcare Private Limited)	Stepdown Subsidiary of AHLL
Apollo Cradle and Children Hospital Private Limited	Stepdown Subsidiary of AHLL
Apollo 24/7 Insurance Services Limited (w.e.f. 3 September 2024)	Subsidiary of AHL
Asclepius Hospitals and Healthcare Private Limited	Subsidiary of Assam
Apollo CVHF Limited	Subsidiary of AHIL
Balayam Healthcare Private Limited	Subsidiary of KFHS
Family Health Plan Insurance (TPA) Limited	Associate



Name of the Company	Relationship
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate
Apollo Medical Private Limited (AMPL)	Associate of AHL
Apollo Pharmacies Limited	Subsidiary of AMPL
Apollo Pharmalogistics Private Limited	Subsidiary of AMPL
Apollo Gleneagles PET-CT Private Limited	Joint venture
ApoKos Rehab Private Limited	Joint venture
Nexify Health Private Limited (w.e.f. 30 September 2024)	Joint venture of HAPL

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 6 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals & Research Centre Limited, by the Government of Karnataka. Our conclusion on the Statement is not modified in respect of this matter.
7. We did not review the interim financial results of 26 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 4,660 million for the three months ended June 30, 2025, total net profit after tax of Rs. 207 million for the three months ended June 30, 2025 and total comprehensive income of Rs. 205 million for the three months ended June 30, 2025, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs. 134 million for the three months ended June 30, 2025 and total comprehensive income of Rs. 144 million for the three months ended June 30, 2025, as considered in the Statement, in respect of 2 joint ventures and 5 associates (including 2 subsidiaries of 1 associate), whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.



**Deloitte
Haskins & Sells LLP**

8. The consolidated unaudited financial results includes the interim financial results of 5 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. Nil for the three months ended June 30, 2025, total loss after tax of Rs.2 million for the three months ended June 30, 2025 and total comprehensive loss of Rs. 2 million for the three months ended June 30, 2025 as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs. Nil for the three months ended June 30, 2025 and total comprehensive income of Rs. Nil for the three months ended June 30, 2025 as considered in the Statement, in respect of 1 associate, based on its interim financial results which have not been reviewed by its auditors. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial results certified by the Management.



For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Nachiappan Subramanian
Partner
Membership No. 218727
UDIN: 25218727BMOEJC6075

Place: Chennai
Date: August 12, 2025

12th August 2025

Apollo Hospitals announces Q1FY26 results

Q1 FY26 Consolidated Revenues grew 15% YoY to Rs. 5,842 Crore

Q1 FY26 Consolidated EBITDA grew 26% YoY to Rs. 852 Crore

Q1 FY26 Consolidated PAT grew 42% YoY to Rs. 433 Crore

During the quarter, AHEL also announced de-merger of its Omni Channel Pharmacy and Digital Health business into a new entity Apollo Healthtech Ltd. to unlock value for existing shareholders

Apollo Children's Hospitals achieved a milestone of completing 6,000 pediatric cardiac surgeries

Launched 'OraLife' for the early detection of oral cancer with the intention to raise awareness and utilizes AI-powered technology for diagnosing the disease

Unveiled Apollo Zen – the most clinically advanced health management program, powered by advanced diagnostics and AI insights for preventive care

Announced expansion of 700 beds in 2 phases in Bengaluru; will take total bed capacity to 1,500 beds

On track to add 4,370 beds through acquisition, brownfield and greenfield expansion over the next 3-4 years

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd. said, "I am proud to see the resilient comeback in the first quarter of FY26, building on the strong foundation of Q4FY25. I am glad to inform you that Q1FY26 has delivered another robust set of results, with revenue growth in the double digits at 15% YoY and continued improvement in margins. Our performance demonstrates the power and resilience of our integrated model of healthcare delivery with all three engines - our core divisions, Healthcare Services, Retail Healthcare & Diagnostics, and Digital & Pharma Distribution, contributing to our performance.

Patient numbers across our network increased year-on-year, reflecting both the deeper penetration of our Centers of Excellence and the growing confidence of communities in our integrated care model. The quarter saw us announce our ambitious growth strategy to add over 4,300 beds in the next five years with an investment of over ₹7,600 crore. The first phase of 2,000 beds is already in progress. We have added an existing 200-bed hospital in Bengaluru and will also be establishing a 500-bed greenfield hospital in the suburbs of the city to bring the total bed strength in Bengaluru to 1,500 beds. In Hyderabad, we are adding 160 beds at our existing Jubilee Hills and Secunderabad facilities, and with the upcoming facility in Gachibowli, our bed strength in the city will increase to 1,400 beds.

On the digital front, Apollo 24/7 achieved a quarterly GMV of over Rs. 682 crore, sustaining the platform's momentum and signaling the continuing strong demand for teleconsultations, lab and pharmacy deliveries. This performance builds on the platform's FY25 GMV of Rs. 3,007 crore, demonstrating our success in creating a seamless care continuum from home to hospital.

The demerger of our digital health and pharmacy business, approved in the last quarter, is now in the implementation phase. This strategic move will enable focused capital allocation and sharper growth plans with dedicated management teams for both hospital operations and omnichannel healthcare ecosystem, a structure designed to maximize synergies while preserving the Apollo ethos of quality and trust.

Preventive healthcare remains at the heart of our mission. Through the AI-based Apollo ProHealth platform, we have crossed 2.5Million health assessments this quarter alone, guiding individuals on personalized wellness journeys and strengthening early -detection pathways.

Patient access continues to guide our investments. We expanded our 'Care-Within-Reach' financing programs to additional tier2 and tier3 markets, ensuring that advanced treatments remain accessible to a broad segment of the population. Our efforts on sustainability saw us launch 'Green Health' initiatives in Mumbai and Hyderabad, achieving a 20% reduction in energy consumption per patient day and using ecofriendly materials across new construction projects.

Looking ahead, we anticipate continued double digit revenue growth for FY26, underpinned by new hospital openings in Patna and Jaipur slated for Q3, further digital innovation, and deepening partnerships with state governments to bolster community-based health initiatives. I remain confident that Apollo will set new benchmarks in clinical excellence, patient experience, and sustainable growth—true to our founding mission of enabling healthier, happier lives for all."

Q1FY26 CONSOLIDATED RESULTS

REVENUE

Q1FY26 Consolidated Revenues grew 15% YoY to Rs. 5,842 Crore;

- Healthcare Services (HCS) Revenue at Rs. 2,935 Crore; 11% YoY growth
- AHLL: Revenues at Rs. 435 Crore; 19% YoY growth
- Apollo HealthCo: Revenues at Rs. 2,472 Crore; 19% YoY growth
- GMV of Apollo 24/7 at Rs. 682 Crore

EBITDA

Q1FY26 Consolidated EBITDA grew 26% YoY to Rs. 852 Crore;

- Healthcare Services (HCS) EBITDA at Rs. 718 Crore; 15% YoY growth
- AHLL EBITDA at Rs. 40 Crore; 31% YoY growth
- Apollo HealthCo: EBITDA at Rs. 94 Crore

PAT

Q1FY26 Consolidated PAT grew 42% YoY to Rs. 433 Crore;

- Healthcare Services (HCS) PAT at Rs. 384 Crore; 17% YoY growth
- AHLL PAT loss of Rs. 8 Crore
- Apollo HealthCo PAT at Rs. 57 Crore

Financial Performance – Q1 FY26

Consolidated Q1 FY26 Performance

- Revenues at Rs. 5,842 crore vs Rs. 5,086 crore in Q1 FY25; growth of 15% YoY
- EBITDA at Rs. 852 crore vs Rs. 675 crore in Q1 FY25. This is after Apollo 24/7 cost of Rs. 121 crore in the quarter (incl. Rs. 24 crore non-cash ESOP charge) vs Rs. 150 crore in Q1 FY25.
- Reported PAT at Rs. 433 crore vs Rs. 305 crore in Q1 FY25
- Diluted EPS of Rs. 30.10 per share in Q1 FY26 (not annualized)

Healthcare service Q1 FY26 Performance

- Revenue at Rs. 2,935 crore vs Rs. 2,637 crore in Q1 FY25; growth of 11% YoY
- EBITDA grew by 15% at Rs. 718 crore vs Rs. 622 crore in Q1 FY25; Margins at 24.5% in Q1 FY26
- PAT stood at Rs. 384 crore vs Rs. 328 crore in Q1 FY25, up 17% YoY

Apollo Health and Lifestyle Limited Q1 FY26 Performance

- Revenue at Rs. 435 crore vs Rs. 366 crore in Q1 FY25; growth of 19% YoY
- EBITDA grew by 31% at Rs. 40 crore vs Rs. 31 crore in Q1 FY25; Margins at 9.3% in Q1 FY26
- PAT loss of Rs. 8 crore vs loss of Rs. 10 crore in Q1 FY25

Apollo HealthCo Q1 FY26 Performance

- Revenue at Rs. 2,472 crore vs Rs. 2,082 crore in Q1 FY25; growth of 19% YoY
- EBITDA at Rs. 94 crore vs Rs. 23 crore in Q1 FY25; Margins at 3.8% in Q1 FY26
- PAT stood at Rs. 57 crore vs loss of Rs. 13 crore in Q1 FY25

Q1 FY26 Segment-wise Performance Update

Healthcare Services (Hospitals)

As on June 30, 2025, Apollo Hospitals had 8,030 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 65% vs 68% in the same period in the previous year.

Consolidated Revenues of the healthcare services division increased by 11% to Rs. 2,935 crore in Q1 FY26 compared to Rs. 2,637 crore in Q1 FY25.

EBITDA (Post Ind AS 116) was at Rs. 718 crore in Q1 FY26 compared to Rs. 622 crore in Q1 FY25. EBITDA was higher by 15% YoY.

Revenues in the **Tamil Nadu** cluster grew by 9%. ARPP grew by 11% to Rs. 2,02,525. Overall occupancy in the cluster was 1,261 beds (62% occupancy) as compared to 1,311 beds (64% occupancy) in the previous year.

In **AP Telangana** region, Revenues grew by 23%, IP volumes grew by 18%. ARPP grew by 7% to Rs. 1,82,518. Occupancy in the cluster was 813 beds (63% occupancy) as compared to 783 beds (63% occupancy) in the previous year.

In **Karnataka** region, Revenues grew by 14%, IP volumes degrew by 2%. ARPP grew by 15% to Rs. 1,76,417. Occupancy in the cluster was 534 beds (69% occupancy) as compared to 569 beds (76% occupancy) in the previous year.

In **Eastern region**, Revenues grew by 7%, IP volumes grew by 1%. ARPP grew by 6% to Rs. 1,45,192. Occupancy in the cluster was 1,301 beds (71% occupancy) as compared to 1,377 beds (75% occupancy) in the previous year.

In **Western region**, Revenues grew by 14%, IP volumes grew by 5%. ARPP grew by 12% to Rs. 1,56,825. Occupancy in the cluster was 465 beds (52% occupancy) as compared to 472 beds (55% occupancy) in the previous year.

In **Northern region**, Revenues grew by 8%, IP volumes grew by 2%. ARPP grew by 6% to Rs. 1,63,930. Occupancy in the cluster was 847 beds (70% occupancy) as compared to 875 beds (72% occupancy) in the previous year.

Apollo Health and Lifestyle Limited: Diagnostics and Retail Healthcare

- AHLL Gross Revenue at Rs. 435 crore; up 19% YoY growth
- Diagnostics Revenue stood at Rs. 152 crore and Spectra at Rs. 81 crore

Apollo HealthCo: Digital Healthcare and Omni-channel Pharmacy platform

- Offline Pharmacy distribution revenues at Rs. 2,163 crore in Q1 FY26 while Revenues from Digital platform were at Rs. 308 crore.
- Overall Health Co Revenues were at Rs. 2,472 crore representing 19% YoY growth.
- 116 net new stores were opened in this quarter, taking the total number to 6,742 stores.
- GMV of Apollo 24/7 at Rs. 682 crore in Q1 FY26, growth of 23% over Q1 FY25.
- Avg Q1 FY26 run rate of 74K/day order across Pharma, Diagnostics Consultations (including IP/OP referrals) compared to 60K/day in Q1 FY25.

Clinical Excellence Highlights

Apollo Hospitals continues to set benchmarks in clinical innovation, reporting **114 advanced treatments and complex cases in Q1 FY 2025–26**. A total of **1,751 robotic surgeries** were performed during the quarter, bringing the **cumulative number of robotic surgeries across the network to 22,145 as of June 2025**, underscoring Apollo's leadership in precision care and advanced surgical technologies.

Tamil Nadu

Apollo Hospitals, Greams Road, Chennai

- Hybrid TEVAR and EVAR for a 75-year-old with a 10 cm thoracoabdominal aneurysm.
- Direct Anterior Total Hip Replacement (THR) using a minimally invasive approach.
- Completion of 1000+ CHIP-PCI procedures since 2019 for high-risk cardiac patients.
- Successful treatment of mitral regurgitation due to calcified amorphous tumor.
- MiniLep (Thulium Laser) for prostatic enlargement as a safer alternative to TURP.

Apollo Children's Hospital, Chennai

- Aorto-pulmonary window repair in a 3-month-old infant using sandwich technique.
- Aberrant subclavian artery repair via right supraclavicular incision in a 7-month-old.

Apollo Women's Hospital, Chennai

- Combined laparoscopic hysterectomy and gastric bypass for adenomyosis.
- Complex multi-organ surgery for uterine mass infiltrating sigmoid colon with high CA-125.

Apollo Specialty Hospitals, Vanagaram

- Marsupialization of RCA pseudoaneurysm with stent infection.
- Balloon implantation for periartthritis shoulder.
- Embolization for Sturge-Weber Syndrome in a 7-year-old.

Apollo Hospitals, Trichy

- Pituitary Apoplexy treated via minimally invasive trans-nasal endoscopic surgery.

Karnataka

Apollo Hospitals, Bangalore

- Sacral Nerve Stimulation (SNS) for urge incontinence post spinal AVM treatment.

Apollo Hospitals, Jayanagar

- First mechanical thrombectomy using INARI FlowTrieve in Karnataka for massive PE.

Apollo BGS Hospitals, Mysore

- Metacarpal reconstruction with fibular allograft for recurrent giant cell tumor.
- ACL reconstruction using JEWEL ACL synthetic graft.
- Splenectomy with PSRS for EHPVO in a 7-year-old.

Maharashtra

Apollo Hospitals, Navi Mumbai

- Impella-assisted PCI with IVUS and rotational atherectomy in an 83-year-old.
- Kasai's Porto-Enterostomy for biliary atresia in a 19-day-old infant.
- Complex revision thyroid surgery for dual cancer pathology with tracheal invasion.

Apollo Hospitals, Nashik

- Complex spinal correction for L1 hemivertebra and scoliosis in a 2-year-old.
- PTCA using Orbital Atherectomy in a 70-year-old with CAD.
- RIRS and cadaveric renal transplant for CKD Stage 5D with renal calculi.
- Flow-diverter stent for subarachnoid hemorrhage in a 36-year-old female.

Telangana & Andhra Pradesh

Apollo Hospitals, Hyderabad

- TAVI for degenerated tissue valve in a 60-year-old.
- Achilles tendon allograft for lower trapezius transfer in chronic shoulder injury.
- First transcatheter PFO closure in Andhra Pradesh-Telangana using Talisman Occluder.

Delhi (NCR)

Indraprastha Apollo Hospitals, Delhi

- North India's first robotic bilateral breast cancer surgery using da Vinci system.
- Reverse shoulder arthroplasty for severe joint degeneration in a Tanzanian patient.
- Targeted therapy for invasive salivary duct carcinoma with intracranial extension.
- Bilateral lung transplant for end-stage ILD.
- Robotic fertility-preserving surgery for cervical cancer in a morbidly obese patient (BMI 66.7).

Gujarat

Apollo Hospitals, Ahmedabad

- India's first Silent Zone Kambin-OLLIF Spine Surgery for nerve-safe spinal implantation.

Uttar Pradesh

Apollo Medics Hospitals, Lucknow

- TAVI using EVOLUT FX valve for symptomatic aortic stenosis.
- Thyroid Artery Embolization (TAE) for large multinodular goiter.
- First regional arthroscopic collagen graft repair for chronic rotator cuff tear.

New Launches, Initiatives and Partnerships

- Apollo Hospitals launched the fifth edition of its *Health of the Nation 2025* report, spotlighting the surge in non-communicable diseases and advocating for proactive, personalized healthcare strategies.
- Apollo Diagnostics launched a fully automated Digi-Smart Central Reference Laboratory in Chennai, integrating advanced technologies to deliver faster and more accurate diagnostics across over 3,000 tests.

Corporate Social Responsibility

Apollo Foundation (Q1 FY 2025–26): Through its diverse philanthropic arms — Apollo Total Health, Billion Hearts Beating, SACHi, and several other initiatives — the Apollo Foundation continues to drive large-scale, meaningful impact across India. These programmes extend far beyond conventional healthcare, addressing critical areas such as paediatric surgeries, community-based healthcare, skill development, livelihood creation, and mental wellness.

In Q1 FY 2025–26,

- Apollo Total Health reached 1,13,172 beneficiaries, delivering integrated healthcare and wellness services at the grassroots level.
- Billion Hearts Beating impacted 93,468 individuals through targeted preventive health and wellness programmes.
- SACHi continued its mission of saving young lives by providing paediatric cardiac surgeries to children from underprivileged backgrounds.
- Other initiatives supported elder care, nutrition, disaster relief, and mental health interventions.

Together, these efforts touched the lives of over 2 lakh individuals in just three months, reaffirming Apollo's commitment to accessible healthcare, preventive screening, and holistic community well-being.

Every intervention is rooted in the belief that good health is the foundation for a stronger, more resilient society.

Awards And Accolades

- Apollo Hospitals International Ltd, Ahmedabad won the Excellence in Multi-Specialty Care – West award at the Financial Express – Express Awards.
- Apollo Hospitals, Healthcity, Visakhapatnam received the Excellence in Orthopedic Care – South award at the Financial Express – Express Awards.
- Apollo Hospitals, Healthcity, Visakhapatnam was honored with the Excellence in Emergency & Critical Care – South award at the Financial Express – Express Awards.

About Apollo

Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world's largest integrated healthcare platform with over 10,000 beds across 73 hospitals, 6,700+ pharmacies, 280+ clinics, 2,200+ diagnostic centers. It is one of the world's leading cardiac centers, having performed over 3,00,000 angioplasties and 2,00,000 surgeries. Apollo continues to invest in research and innovation to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have access to the best care in the world. Apollo's 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.

For further details, log onto: www.apollohospitals.com

For further information, please contact:

For Media / Investors

R Krishnakumar
Apollo Hospitals Ltd.
Krishnakumar_r@apollohospitals.com
+91 44 2829 7840

Mayank Vaswani
CDR India
mayank@cdr-india.com
+91 22 6645 1230

Disclaimer

Some of the statements in this document that are not historical facts are forward looking statements. These forward-looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate.

These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward-looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly-competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry.

Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.